{"nctId":"NCT02600507","briefTitle":"Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression","startDateStruct":{"date":"2016-03-07","type":"ACTUAL"},"conditions":["Bipolar Depression"],"count":529,"armGroups":[{"label":"Lumateperone 28 mg (ITI-007 40 mg tosylate)","type":"EXPERIMENTAL","interventionNames":["Drug: Lumateperone (ITI-007)"]},{"label":"Lumateperone 42 mg (ITI-007 60 mg tosylate)","type":"EXPERIMENTAL","interventionNames":["Drug: Lumateperone (ITI-007)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Lumateperone (ITI-007)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* male or female subjects of any race, ages 18-75 inclusive, with a clinical diagnosis of Bipolar I or Bipolar II disorder\n* experiencing a current major depressive episode\n* treatment with either lithium or valproate and inadequate therapeutic response of depressive symptoms\n\nExclusion Criteria:\n\n* any subject unable to provide informed consent\n* any female subject who is pregnant or breastfeeding\n* any subject judged to be medically inappropriate for study participation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score","description":"The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.2","spread":"0.79"},{"groupId":"OG001","value":"-16.9","spread":"0.81"},{"groupId":"OG002","value":"-14.5","spread":"0.79"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression Scale-Bipolar Version-Severity (CGI-BP-S) Depression Score","description":"The Clinical Global Impression Scale-Bipolar Version-Severity (CGI-BP-S) Depression Score is a clinician-rated scale that measures the patient's current state of depression from 1 (not ill at all) to 7 (among the most extremely ill).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"0.09"},{"groupId":"OG001","value":"-1.8","spread":"0.10"},{"groupId":"OG002","value":"-1.5","spread":"0.09"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":176},"commonTop":["Headache","Dizziness","Somnolence","Nausea"]}}}